ストックスクリーナーアプリを入手
102.68
3.24%
3.22
アフターアワーズ：
102.40
-0.28
-0.27%
前日終値:
$99.46
開ける：
$100.265
24時間の取引高:
4.65M
Relative Volume:
1.65
時価総額：
$17.27B
収益：
$381.03M
当期純損益:
$-1.01B
株価収益率:
-17.26
EPS:
-5.95
ネットキャッシュフロー:
$-789.25M
1週間 パフォーマンス:
+4.00%
1か月 パフォーマンス:
+49.88%
6か月 パフォーマンス:
+45.77%
1年 パフォーマンス:
+58.68%
1日の値動き範囲:
$99.02
$102.81
1週間の範囲:
$97.79
$102.81
52週間の値動き範囲:
$60.40
$102.81
Insmed Inc Stock (INSM) Company Profile
INSM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
102.68 | 17.27B | 381.03M | -1.01B | -789.25M | -5.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-13 | 開始されました | Jefferies | Buy |
| 2025-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-04-23 | 開始されました | Truist | Buy |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-07-26 | 開始されました | Guggenheim | Buy |
| 2022-12-09 | 開始されました | Mizuho | Buy |
| 2022-12-07 | 開始されました | Barclays | Overweight |
| 2022-11-18 | 開始されました | BofA Securities | Buy |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2021-12-06 | 開始されました | JP Morgan | Overweight |
| 2021-10-19 | 再開されました | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-10-12 | 再開されました | Stifel | Buy |
| 2019-09-03 | 開始されました | Goldman | Buy |
| 2019-04-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-15 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | アップグレード | Goldman | Neutral → Buy |
| 2019-01-02 | 開始されました | Canaccord Genuity | Buy |
| 2018-08-06 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 開始されました | Goldman | Neutral |
| 2018-04-23 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 開始されました | Morgan Stanley | Overweight |
| 2018-01-18 | 開始されました | Credit Suisse | Neutral |
| 2017-09-05 | 繰り返されました | Evercore ISI | Outperform |
| 2017-08-17 | 開始されました | Evercore ISI | Outperform |
| 2017-07-11 | 開始されました | Robert W. Baird | Outperform |
| 2016-03-15 | 開始されました | Stifel | Buy |
| 2015-11-09 | ダウングレード | UBS | Buy → Neutral |
| 2015-10-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-06-09 | 開始されました | Citigroup | Neutral |
| 2014-03-26 | 繰り返されました | HC Wainwright | Buy |
すべてを表示
Insmed Inc (INSM) 最新ニュース
Insider Sell: Roger Adsett Sells 10,686 Shares of Insmed Inc (INSM) - GuruFocus
Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110 - Insider Monkey
10 Best Growth Stocks to Buy According to Billionaires - Insider Monkey
Wells Fargo Lifts Price Target on Insmed Incorporated (INSM) to $119 From $107 - Insider Monkey
Is Insmed Stock Overvalued at $98? - Nasdaq
Goldman Sachs Hikes Insmed (INSM) Price Target to $112 Affirms Buy Rating - Insider Monkey
Insmed Completes $750 Million Follow-On Public Offering - Global Legal Chronicle
Is Insmed Stock Overvalued After The 45% Jump? - Forbes
Oracle, AST SpaceMobile And Halliburton Are Among Top 10 Large Cap Gainers Last Week (June 9-13): Are The Others In Your Portfolio? - Benzinga
Insmed Inc (INSM) Soars 30% on Impressive Study - MSN
Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results - Insider Monkey
INSM September 19th Options Begin Trading - Nasdaq
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans - Yahoo Finance
Insmed (INSM) Soars After Raising $650 million - MSN
Insmed Stock Jumps 29% on Encouraging PAH Study Results - MSN
Finance Watch: Insmed Cashes In On Positive Data With $750m Offering - insights.citeline.com
SEC Form 424B5 filed by Insmed Incorporated - Quantisnow
Insmed prices capital raise of $750 via stock offering - MSN
Insmed announces $650M public offering of common stock - MSN
Insmed Stock Ends Volatile Session Lower, Pauses After Monumental 32% Weekly Surge - Daily Chhattisgarh News
Insmed aims to raise $750M in one of the largest stock offerings this year - Endpoints News
Stocks To Watch: Insmed Sees RS Rating Jump To 93 - MSN
Insmed dips after $750 mln stock sale - TradingView
Insmed (INSM) Secures $750 Million Through Stock Offering - GuruFocus
Insmed is an attractive, but expensive takeout meal - statnews.com
INSM Increases Common Stock Offering to $750M | INSM Stock News - GuruFocus
Insmed Prices $750 Million Common Stock Offering - MarketScreener
Bank of America Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price - Defense World
Insmed Raises Massive $750M in Stock Offering to Advance Breakthrough Drug Pipeline - Stock Titan
INSM: Mizuho Raises Price Target for Insmed to $110 | INSM Stock News - GuruFocus
Insmed Prices Public Offering Of About 7.81 Mln Shares At $96.00/shr - Nasdaq
Insmed raises $750 million in public offering of common stock By Investing.com - Investing.com Canada
Insmed Announces Pricing of $750 Million Public Offering of Comm - GuruFocus
Insmed raises $750 million in public offering of common stock - Investing.com
Insmed Announces Pricing Of $750 Million Public Offering Of Common Stock At $96 Per Share - marketscreener.com
Insmed Announces Pricing of $750 Million Public Offering of Common Stock - marketscreener.com
These 10 Stocks Are Flying High - Insider Monkey
Insmed (INSM) Plans $650M Public Offering of Common Stock | INSM - GuruFocus
Insmed's drug for rare lung disease meets main goal in mid-stage trial - MSN
Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM) - Yahoo Finance
$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today - Benzinga
Insmed (INSM) Sees Price Target Boost Amid Strong PAH Data | INS - GuruFocus
Insmed (INSM) Price Target Raised to $120 by HC Wainwright & Co. - GuruFocus
Insmed (INSM) Plans $650M Stock Offering, Shares Fall - GuruFocus
Insmed announces $650 million public offering of common stock - Investing.com
Insmed announces $650 million public offering of common stock By Investing.com - Investing.com Canada
Insmed Plans $650 Million Public Offering - marketscreener.com
Insmed announces $650M common stock offering - TipRanks
Insmed Announces Proposed $650 Million Public Offering of Common Stock | INSM Stock News - GuruFocus
Insmed (INSM) Sees Boost with Positive Phase 2b Trial Results | - GuruFocus
Insmed (INSM) Receives Boosted Price Target from Wells Fargo | I - GuruFocus
Insmed Inc (INSM) 財務データ
収益
当期純利益
現金流量
EPS
Insmed Inc (INSM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Jun 16 '25 |
Sale |
100.39 |
129,805 |
13,031,681 |
233,924 |
| Lewis William | Chair and CEO |
Jun 16 '25 |
Sale |
100.32 |
5,204 |
522,063 |
303,554 |
| Adsett Roger | Chief Operating Officer |
Jun 16 '25 |
Sale |
98.82 |
10,686 |
1,056,004 |
130,637 |
1.98%
0.14%
大文字化:
|
ボリューム (24 時間):